aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders, closed a $12M Series C financing. Participants include Alta Partners, Cardinal Partners and Polaris Ventures.

Limerick BioPharma (San Francisco, CA) a clinical-stage biopharmaceutical company focused on the modulation of cellular pumps and other transporters, closed a $15M Series C financing. Participants include OVP Venture Partners, ARCH Venture Partners, Sevin Rosen Funds and Altitude Funds.

Aileron Therapeutics (Cambridge, MA) a pre-clinical large molecule biopharmaceutical company focused on oncology, inflammation and metabolic and infectious diseases, closed a $40M Series D financing. Participants include Excel Medical Ventures, SR One, Lilly Ventures, Roche Venture Fund, Apple Tree Partners and Novartis Venture Funds.

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source, added to their Series B financing bringing the round up to $17.5M. Participants include Braemar Energy Ventures, Altira Group, Mohr Davidow Ventures and X/Seed Capital.

Surface Logix (Brighton, MA) a clinical-stage small molecule company focused on metabolic and cardiovascular disease, closed a $15M Series E financing. Participants include ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Co., Unilever Technology Ventures and Venrock.

ActoGeniX (Belgium) a clinical-stage biopharmaceutical company focused on the development
of protein therapeutics for the treatment of gastrointestinal and metabolic diseases, closed a $17.1M Series B financing. Participants include Biovest, Gimv, Biotech Fund Flanders, Baekeland Fund, VIB, LSP, Aescap Venture and Ventech.

7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, [...]

Arete Therapeutics (Hayward, CA) clinical-stage biotechnology company developing soluble epoxide hydrolase inhibitor small molecule drugs for the treatment of cardiovascular, metabolic and inflammatory diseases, closed a $51M Series A financing. Participants include Frazier Healthcare Ventures, Alta Partners, Burrill & Co., Three Arch Partners, and Altitude Life Science Ventures.